{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:17:05Z","timestamp":1787894225480,"version":"build-2784847793"},"reference-count":147,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2705803"],"award-info":[{"award-number":["2023YFC2705803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82471767"],"award-info":[{"award-number":["82471767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["82471767"],"award-info":[{"award-number":["82471767"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["UGG04397"],"award-info":[{"award-number":["UGG04397"]}]},{"award":["UGG04397"],"award-info":[{"award-number":["UGG04397"]}],"id":[{"id":"https:\/\/ror.org\/04jztag35","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Key Clinical Specialty Construction Project","award":["U114000"],"award-info":[{"award-number":["U114000"]}]},{"name":"Fundamental Research Funds for Central Universities, Chinese Academy of Medical Sciences & Peking Union Medical College","award":["3332026082"],"award-info":[{"award-number":["3332026082"]}]},{"award":["3332026082"],"award-info":[{"award-number":["3332026082"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint blockade has become an important component of treatment for several gynecologic malignancies, but its clinical value varies substantially by tumor lineage, molecular subtype, disease setting, and treatment backbone. This narrative review summarizes the biological rationale, clinical evidence, predictive biomarkers, combination strategies, toxicity considerations, and future directions of immunotherapy across gynecologic cancers. In cervical cancer, checkpoint blockade has evolved from later-line recurrent disease to first-line systemic therapy and, more recently, to curative-intent chemoradiotherapy combinations. In endometrial cancer, mismatch repair-deficient\/microsatellite instability-high (dMMR\/MSI-H) tumors show the clearest sensitivity to programmed cell death protein 1 (PD-1) blockade, whereas mismatch repair-proficient\/microsatellite stable (pMMR\/MSS) disease generally requires combination strategies. In ovarian cancer, broad unselected checkpoint inhibitor strategies have generally failed; ENGOT-ov65\/KEYNOTE-B96 demonstrated statistically significant progression-free survival (PFS) and overall survival (OS) improvement with pembrolizumab plus weekly paclitaxel, with or without bevacizumab, in a defined platinum-resistant population, although the absolute median PFS gain in PD-L1 combined positive score (CPS) \u22651 disease was modest. Gestational trophoblastic neoplasia (GTN) offers a biologically distinctive setting because of trophoblastic immune tolerance, whereas selected rare gynecologic malignancies may be considered for immunotherapy on the basis of HPV association, tumor-agnostic biomarkers, or signals observed in clear-cell cohorts. Accordingly, the clinical value of immunotherapy should be interpreted according to tumor lineage, disease setting, validated biomarkers, treatment backbone, and the incremental contribution of each treatment component.<\/jats:p>","DOI":"10.3390\/cancers18172771","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:59:23Z","timestamp":1787741963000},"page":"2771","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5184-4885","authenticated-orcid":false,"given":"Chen","family":"Yang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Women\u2019s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Women\u2019s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-0119","authenticated-orcid":false,"given":"Junjun","family":"Yang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Women\u2019s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Women\u2019s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"04155","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J. Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase III trial","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: Final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase III trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): A randomised, double-blind, phase III clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): A randomised, double-blind, phase III trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): Overall survival results from a randomised, double-blind, placebo-controlled, phase III trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): A randomised, double-blind, placebo-controlled, phase III trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines Insights: Uterine Neoplasms, Version 3.2025","volume":"23","author":"Campos","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pal, A., and Kundu, R. (2019). Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.03116"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semradonc.2021.02.008","article-title":"Immunotherapy for HPV malignancies","volume":"31","author":"Lee","year":"2021","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"Eggink","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study","volume":"11","author":"Quint","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: Facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"A simple genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Britton","year":"2020","journal-title":"J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Updated results from the KEYNOTE-158 study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III Study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41698-024-00640-8","article-title":"Spatial tumor immune microenvironment phenotypes in ovarian cancer","volume":"8","author":"Mateiou","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41590-024-01943-5","article-title":"Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer","volume":"25","author":"Yeh","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian cancer: Are we there yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8-positive tumor-infiltrating lymphocytes and a high CD8-positive\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","unstructured":"Ovarian Tumor Tissue Analysis (OTTA) Consortium (2017). Dose-response association of CD8-positive tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol., 3, e173290."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","article-title":"Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells","volume":"40","author":"Anadon","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Cybulska","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13073-021-00922-x","article-title":"High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: Specific cell subtypes influence survival and determine molecular subtype classification","volume":"13","author":"Olbrecht","year":"2021","journal-title":"Genome Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Almeida-Nunes, D.L., Mendes-Frias, A., Silvestre, R., Dinis-Oliveira, R.J., and Ricardo, S. (2022). Immune tumor microenvironment in ovarian cancer ascites. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810692"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/IGC.0000000000000892","article-title":"PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes","volume":"27","author":"Bolze","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/his.13882","article-title":"PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia","volume":"75","author":"Zong","year":"2019","journal-title":"Histopathology"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zhuang, B., Shang, J., and Yao, Y. (2021). HLA-G: An important mediator of maternal-fetal immune-tolerance. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.744324"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijgo.13877","article-title":"Diagnosis and management of gestational trophoblastic disease: 2021 update","volume":"155","author":"Ngan","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hoc.2024.07.001","article-title":"Diagnosis and management of molar pregnancies","volume":"38","author":"Braga","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ajog.2010.06.073","article-title":"Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole","volume":"203","author":"Lurain","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"115146","DOI":"10.1016\/j.ejca.2024.115146","article-title":"Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9 trial","volume":"216","author":"Oaknin","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): A randomised, double-blind, placebo-controlled phase III trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: A randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Cibula","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): An open-label, randomised, phase III trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase III study","volume":"22","author":"Fujiwara","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): A multicentre, randomised, double-blind, phase III study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2023.06.018","article-title":"Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050\/GOG 3015\/ENGOT-OV39 trial","volume":"177","author":"Pignata","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"101704","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Moore","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1200\/JCO.20.00803","article-title":"Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: Cohort A of the TROPHIMMUN phase II trial","volume":"38","author":"You","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2022.11.005","article-title":"Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial","volume":"168","author":"You","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","article-title":"Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): A single-arm, open-label, phase 2 trial","volume":"22","author":"Cheng","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1470-2045(24)00088-3","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): A phase 1\u20132, open-label, multicohort trial","volume":"25","author":"Oaknin","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e004232","DOI":"10.1136\/jitc-2021-004232","article-title":"ISA101 and nivolumab for HPV-16-positive cancer: Updated clinical efficacy and immune correlates of response","volume":"10","author":"Sousa","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Mileshkin","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41598-021-83317-7","article-title":"Pembrolizumab in vaginal and vulvar squamous cell carcinoma: A case series from a phase II basket trial","volume":"11","author":"How","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaoncol.2015.6326","article-title":"Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva","volume":"2","author":"Howitt","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high or proficient\/stable endometrial cancer: Interim results from GARNET","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/cas.15497","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"113","author":"Nagasaki","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2023.09.012","article-title":"Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100","volume":"178","author":"Ledermann","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with advanced clear cell gynecological cancer: A phase 2 nonrandomized clinical trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2025.1916","article-title":"Nivolumab and ipilimumab combination treatment in advanced ovarian and endometrial clear cell cancers: A nonrandomized clinical trial","volume":"11","author":"Gao","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100701","DOI":"10.1016\/j.gore.2021.100701","article-title":"Use of pembrolizumab in MSI-high uterine leiomyosarcoma: A case report and review of the literature","volume":"35","author":"Wang","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/his.15112","article-title":"PD-L1 expression in vulvar cancer: A systematic review and meta-analysis","volume":"84","author":"Baandrup","year":"2024","journal-title":"Histopathology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2023.12.025","article-title":"Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies","volume":"182","author":"Recio","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2024.11.002","article-title":"The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer","volume":"192","author":"Shu","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-naive platinum-sensitive relapsed ovarian cancer: A phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: A phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): A phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"RAINBO Research Consortium (2023). Refining adjuvant treatment in endometrial cancer based on molecular features: The RAINBO clinical trial program. Int. J. Gynecol. Cancer, 33, 109\u2013117.","DOI":"10.1136\/ijgc-2022-004039"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijgo.70275","article-title":"Diagnosis and management of gestational trophoblastic disease: 2025 update","volume":"171","author":"Ngan","year":"2025","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"101974","DOI":"10.1016\/j.eclinm.2023.101974","article-title":"Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: A multicenter, retrospective study","volume":"59","author":"Wang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaoncol.2026.1697","article-title":"Avelumab plus methotrexate for gestational trophoblastic tumors: The TROPHAMET phase 1\/2 nonrandomized clinical trial","volume":"12","author":"You","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"100583","DOI":"10.1016\/j.clinsp.2025.100583","article-title":"Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with subgroup analysis of potential prognostic factors","volume":"80","author":"Barcellos","year":"2025","journal-title":"Clinics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): A multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2022.05.003","article-title":"Immunotherapy toxicities: An SGO clinical practice statement","volume":"166","author":"Clark","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"100276","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: A systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2022.03.031","article-title":"Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis","volume":"165","author":"Barrington","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Huo, G., Song, Y., Liu, W., Guo, H., and Chen, P. (2024). Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1391896"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2771\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:22:41Z","timestamp":1787890961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":147,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172771"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172771","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}